VolitionRx (VNRX) - חוב לטווח ארוך להון

VolitionRx Limited (VNRX) is expanding its B2B presence by implementing Nu.Q diagnostics in laboratories. The long-term debt-to-capital coverage ratio demonstrates financial stability, where the level of 0.00 reflects the current magnitude. However, a deficit of stable cash flows forces the company to rely on external capital. Growth prospects are based on accessible cancer screening via epigenetic blood analysis.

For the non-cyclical cancer early detection business of VolitionRx Limited (VNRX), the long-term debt-to-equity coverage ratio serves as an indicator of financial stability. This metric compares liabilities with a maturity of over one year against the company's net asset value. A decrease in this value indicates an increase in the issuer's debt independence. While high leverage creates risks, an excess of equity may signify an inefficient use of borrowed funds. It is critical for the investor to find a balance between security and yield.